Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Elu...(nt care by combiningthe latest medical d...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
Date:7/9/2008
nt care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
'/>"/>
| SOURCE Abbott Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3
[0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference[0] China Biologic Products to Ring NASDAQ Opening Bell[0] Martek Signs Sole-Source Supply Agreement with Fonterra[0] Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
Other Biology Technology:International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 2International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 3deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 2deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 3deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 4
Breaking Biology News(10 mins):Synthetic protein mimics structure, function of metalloprotein in nature 2Potential new heart attack biomarker uncovered 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Keep Up With Checkups Puts Prevention First 51928 1Keep Up With Checkups Puts Prevention First 51928 2Facial Plastic Surgeon Dr Frank Fechner Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 51924 1Facial Plastic Surgeon Dr Frank Fechner Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 51924 2Facial Plastic Surgeon Dr Frank Fechner Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 51924 3Michigan Chamber of Commerce Joins Americans Against Food Taxes 3B Calls Health Care Reform Effort a Job Killer 51920 1
Other Biology News:Evolution education is a 'must' says coalition of scientific and teaching organizations 2Resilience concepts poised to aid management of coastal marine ecosystems 2Study examines genetic defects linked to body abnormalities in patients with childhood cancer 2
Biology Products:
BRASMC (B950-05) from European Collection of Cell Cultures (ECACC)Mouse Anti-Sulfadimethoxine Monoclonal Antibody, Unconjugated, Clone CH-2027 from Santa Cruz Biotechnology, Inc.BEnEpC (B932-05) from European Collection of Cell Cultures (ECACC)Mouse Anti-Human SM22 alpha Monoclonal Antibody, Unconjugated Conjugated, Clone 10H12 from Vision BioSystems
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |